ELTX

Elicio Therapeutics, Inc.

2.40 USD

Last updated Sep 5, 12:00 UTC

Yesterday HIGH

$2.5

Yesterday LOW

$2.36

52w HIGH

$16

52w LOW

$2.36

EPS

-0.43

PE

-5.58

Next Earnings

Nov 12, 2026

Overview News Unusual Options Flow Insider Transactions Government Trades Fundamentals

Elicio Therapeutics, Inc. stock is down -23.57% since 30 days ago. The next earnings date is Nov 12, 2026. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 50% of the previous 5 September’s closed higher than August. In the last 1 Unusual Options Trades, there were 1 CALL. 100% of analysts rate it a buy.

Options Flow Last 10
Date & Time	Expiration Date	Strike Price	Trade Type	Size	Open Interest

18 Aug 14:01	21 Aug, 2026	2.50	CALL	422	1394

Advanced Data Unlock

Benzinga Newsdesk

Tue Jun 16, 2026

Jones Trading Downgrades Elicio Therapeutics to Hold

Jones Trading analyst Boris Peaker downgrades Elicio Therapeutics (NASDAQ:ELTX) from Buy to Hold.
Benzinga Insights

Mon Jun 15, 2026

12 Health Care Stocks Moving In Monday's Intraday Session
Vandana Singh

Mon Jun 15, 2026

Elicio Therapeutics Pancreatic Cancer Study Disappoints

Elicio Therapeutics reports mixed Phase 2 pancreatic cancer results, identifies key patient subgroup benefit, and outlines Phase 3 plans.
Avi Kapoor

Mon Jun 15, 2026

Crude Oil Tumbles Over 5%; Empire State Manufacturing Index Falls In June

US stocks gain on peace agreement with Iran, Nasdaq up 2%, Dow up 1.1%, S&P 500 up 1.54%. Tech shares jump 2.8%, energy stocks fall 3.5%. Empire State manufacturing index drops to 5.7. Industrial production up 0.1%. Housing market index declines to 35.
Benzinga Newsdesk

Mon Jun 15, 2026

Elicio Therapeutics shares are trading lower after the company announced that its AMPLIFY-7P study did not meet its pre-specified primary DFS endpoint in the intent-to-treat population.
Avi Kapoor

Mon Jun 15, 2026

Dow Jumps Over 600 Points Following US-Iran Peace Deal

US stocks rise on peace agreement with Iran, Dow up 600 points. Tech sector jumps, energy stocks down. Trump announces deal, oil futures decline.
Benzinga Newsdesk

Mon Jun 15, 2026

HC Wainwright & Co. Maintains Buy on Elicio Therapeutics, Raises Price Target to $23

HC Wainwright & Co. analyst Robert Burns maintains Elicio Therapeutics (NASDAQ:ELTX) with a Buy and raises the price target from $17 to $23.
Benzinga Insights

Mon Jun 15, 2026

10 Health Care Stocks Moving In Monday's Pre-Market Session
Benzinga Newsdesk

Mon Jun 15, 2026

Trading Halt: Halt status updated at 7:25:00 AM ET: Quotation Resumption: News and Resumption Times
Benzinga Newsdesk

Mon Jun 15, 2026

Elicio Therapeutics Reports Results From Randomized Phase 2 AMPLIFY-7P Study Evaluating ELI-002 7P In Patients With Adjuvant mKRAS-Driven Pancreatic Ductal Adenocarcinoma

AMPLIFY-7P did not meet the pre-specified primary endpoint of disease-free survival ("DFS") in the intent-to-treat population.Randomization balanced most prognostic factors between arms. However, the ELI-002 7P arm had a

HC Wainwright & Co.

Tue Aug 18, 13:26

buy

confirm

Advanced Data Unlock

Julian Adams, Director

Mon Aug 31, 2026

ELTX Recent Insider Trades and Stock Chart

21,750 shares awarded
Carol Ashe, Director

Mon Aug 31, 2026

ELTX Recent Insider Trades and Stock Chart

21,750 shares awarded
Yekaterina Chudnovsky, Director

Mon Aug 31, 2026

ELTX Recent Insider Trades and Stock Chart

21,750 shares awarded
Allen Nissenson, Director

Mon Aug 31, 2026

ELTX Recent Insider Trades and Stock Chart

21,750 shares awarded
Robert Ruffolo, Director

Mon Aug 31, 2026

ELTX Recent Insider Trades and Stock Chart

21,750 shares awarded
Karen Wilson, Director

Mon Aug 31, 2026

ELTX Recent Insider Trades and Stock Chart

21,750 shares awarded
Jay Venkatesan, Director

Mon Aug 31, 2026

ELTX Recent Insider Trades and Stock Chart

21,750 shares awarded